KOSDAQ - Delayed Quote KRW

EuBiologics Co., Ltd. (206650.KQ)

13,100.00
-170.00
(-1.28%)
At close: May 23 at 3:30:11 PM GMT+9
Loading Chart for 206650.KQ
  • Previous Close 13,270.00
  • Open 13,420.00
  • Bid 13,240.00 x --
  • Ask 13,250.00 x --
  • Day's Range 13,070.00 - 13,490.00
  • 52 Week Range 9,350.00 - 18,800.00
  • Volume 186,510
  • Avg. Volume 190,006
  • Market Cap (intraday) 478.599B
  • Beta (5Y Monthly) 1.60
  • PE Ratio (TTM) --
  • EPS (TTM) --
  • Earnings Date --
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

EuBiologics Co., Ltd., a biopharmaceutical company, provides vaccines for epidemics in South Korea. It offers Euvichol Plus, an oral cholera prevention vaccine; and rCRM197, a diphtheria toxoid vaccine. The company also provides EcML, a vaccine for cell membrane, as well as offers COVID-19 diagnostic kits. In addition, it offers CMO services comprising of drug product production, cell bank production, and drug substance production. Further, the company provides CRMO services, including cell line development, GMP production, validation, and the regulatory support; and operates facilities that manufacture protein-based therapeutics and antibodies. Additionally, it offers contract testing services that include lot release, stability, raw material, and method validation testing services. EuBiologics Co., Ltd. was founded in 2010 and is headquartered in Seoul, South Korea.

www.eubiologics.com

--

Full Time Employees

December 31

Fiscal Year Ends

Recent News: 206650.KQ

View More

Performance Overview: 206650.KQ

Trailing total returns as of 5/23/2025, which may include dividends or other distributions. Benchmark is KOSPI Composite Index (^KS11) .

YTD Return

206650.KQ
7.82%
KOSPI Composite Index (^KS11)
8.03%

1-Year Return

206650.KQ
8.71%
KOSPI Composite Index (^KS11)
4.77%

3-Year Return

206650.KQ
25.78%
KOSPI Composite Index (^KS11)
2.09%

5-Year Return

206650.KQ
86.88%
KOSPI Composite Index (^KS11)
31.57%

Compare To: 206650.KQ

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 206650.KQ

View More

Valuation Measures

Annual
As of 5/23/2025
  • Market Cap

    478.60B

  • Enterprise Value

    430.85B

  • Trailing P/E

    12.49

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    3.93

  • Price/Book (mrq)

    3.24

  • Enterprise Value/Revenue

    3.58

  • Enterprise Value/EBITDA

    8.75

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -20.01%

  • Return on Assets (ttm)

    3.07%

  • Return on Equity (ttm)

    -13.70%

  • Revenue (ttm)

    69.37B

  • Net Income Avi to Common (ttm)

    -13.88B

  • Diluted EPS (ttm)

    --

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    11.49B

  • Total Debt/Equity (mrq)

    14.10%

  • Levered Free Cash Flow (ttm)

    -30.18B

Research Analysis: 206650.KQ

View More

Company Insights: 206650.KQ

Research Reports: 206650.KQ

View More

People Also Watch